SRNE vs TGT · $385.9K cap vs P/E 17, rev $51.98B
Sorrento Therape (SRNE) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Sorrento Therape (SRNE) is a biotechnology company listed on OTCQB.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
SRNE does not have a complete income-statement cache yet.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
SRNE currently screens at market cap $385.9K. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the SRNE and TGT stock pages for the full models.
Not investment advice.